Discussion  by unknown
logit pmedsj ¼ amedsþbvoljþ3medsj
where j denotes the jth of 733 hospitals, p denotes the hos-
pital’s true underlying failure rate for the indicated measure,
vol denotes the hospital’s 2007 CABG volume, and x de-
notes a summary measure of case mix for the indicated out-
come during the indicated time period.4 The remaining
symbols represent unknown parameters to be estimated
from the data. The overall composite score was defined as
a weighted average of the domain-specific probabilities,
with weights proportional to the reciprocal of the standard
deviation. Average composite scores (posterior mean and
95% CI) were determined for each volume category, and
the proportion of variation in the composite scores explained
by volume was calculated.
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The model used for the composite score determination dif-
fers from the other models described in this study: (1) all 4
quality domains are analyzed jointly in a single model; (2)
the model has a single coefficient for volume rather than
a separate volume coefficient for each end point; and (3)
the model was estimated by using hospital-aggregated sum-
mary data (to facilitate computation) instead of individual
patient-level data. At each hospital, the number of ‘‘fail-
ures’’ of each type (mortality, morbidity, ITA noncompli-
ance, and medication noncompliance) was assumed to
depend on volume, case mix (mortality and morbidity
only), and a hospital-specific random-effects parameter.
The inclusion of hospital-specific random effects is intended
to capture variation in performance that is not explained by
volume, case mix, or chance. The model is as follows:
logit pmortj ¼ amortþbvoljþgmortlogit xmortj þ 3mortj
logit pmorbj ¼ amorbþbvoljþgmorblogit xmorbj þ 3morbj
logit pimaj ¼ aimaþbvoljþ3imaj
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Dr T. Bruce Ferguson (Greenville, NC). Thank you, Dr Patter-
son. I have no disclosures. This study extends the CABG volume–
outcome relationship beyond mortality alone to an evaluation of
morbidity and processes of care. Among the most sophisticated
of STS database analyses thus far, I congratulate Dr Shahian and
his coworkers on this work. This analysis highlights what we all
know: it is very difficult to provide continuous, highest-quality de-
livery of standardized care practices unless you ‘‘keep your edge.’’
Although the magic number for annual CABG volume is unknown,
re-examination in light of overall decreasing CABG volumes na-
tionwide is merited. However, the lack of variability across the
country is all the more remarkable when compared with the 10-
fold differences in procedure volume for CABG. This is a direct tes-
tament to the deliberate focus on measuring and disseminating best
practices by our specialty and in moving beyond risk-adjusted out-
comes to processes of care. I have 2 questions for Dr Shahian.
First, the composite score domains–adjusted odds ratio shows
differences in hospital mortality and ITA use but not in morbidity
and medication failure. Because ITA use has been linked to im-
proved short- and long-term mortality and because both ITA use
and, to a degree, hospital mortality are surgeon dependent, does
your analysis suggest that individual provider–level evaluation
rather than hospital-level evaluation is inevitable?
Second, STS risk-adjusted mortality and morbidity have been
stable over the past 3 years and have not continued to decrease.
The 2 lowest-volume groups comprise only 14.4% of the total pa-
tients undergoing CABG, and incremental improvement in their
outcomes through whatever mechanism is not likely to affect these
national benchmarks. What is next for CABG quality improve-
ment? Thank you.
Dr Shahian. Thank you very much, Bruce. With regard to the
first question about individual surgeon– versus hospital-level per-
formance evaluation, our professional societies have historically
focused on the latter. However, there are numerous reports from
Ed Hannan in New York, as well as a paper presented 2 years
ago at this meeting by Joe Carey from California, suggesting that
the surgeon and his or her relationship with the rest of the teamrdiovascular Surgery c Volume 139, Number 2 281
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Dare very important factors in achieving optimal outcomes. In fact,
Bruce, you have mentioned one performance metric, use of the
ITA, in which surgeons are completely in charge of an important
process metric, and there are very few legitimate reasons not to
use an ITA graft.
So how do we best incorporate surgeon performance into an
overall quality-monitoring paradigm while hopefully not causing
surgeons to become risk averse? Like politics, I think this might
be best conducted locally, at least initially. For example, a hospital
chief of cardiac surgery or the leader of a practice group would
carefully review his or her performance reports from the STS data-
base, notice a low score resulting from suboptimal ITA use, drill
down internally to the surgeon level, and then discuss this with
the appropriate staff. As a profession, we have been rather reluctant
to have those kinds of difficult conversations. However, if we do
not accept this responsibility, then others will force the issue, and
the result will be even more onerous.
Your second question involved where we go from here in
quality improvement. First, I would not discount the value of
focusing some improvement efforts on the 2 lowest-volume
hospital categories. Even though they cared for only 14% of
the patients in our series, they include about 36% of hospitals
overall and their performance in most areas appears inferior to
that of larger hospitals.
So what do I think we need to be doing in the quality assurance
and improvement areas? First, we need to develop a broader port-
folio of evidence-based processes of care that is much more com-
prehensive than we currently measure. We need to implement
these nationally using state and regional peer collaboration, and
we need to reduce the variability that currently exists for many of
such measures. We also need enhanced performance monitoring,
particularly in the low-volume programs, where this is so problem-
atic. I personally think that tertiary sponsorship or oversight of the282 The Journal of Thoracic and Cardiovascular Surglowest-volume programs is very important, and this is a model that
has worked well in Massachusetts. Finally, I think there are some
extremely low-volume programs for which regionalization would
be a better option. Thank you.
Dr Craig R. Smith (New York, NY). Very simply, did you look
at geography as a variable at all, state or region, or, more interest-
ingly, is rural low volume the same as urban low volume?
Dr Shahian. We did not look at that, but it would be an excellent
next step.
Dr JohnD. Puskas (Atlanta, Ga). David, I enjoyed your presen-
tation. Did you have a chance to look at the effect of low- or
high-volume centers on mortality and morbidity after off-pump
compared with on-pump surgery? We are still in an era in which
many consider that a more technically demanding operation.
Does an institution or surgeon need to be doing more of it to hit
a decent benchmark in quality?
Dr Shahian. John, we did not do that, but it would be an excel-
lent follow-on study. You are absolutely correct that it is a very in-
teresting and important area to investigate.
Dr Marc R. Moon (St Louis, Mo). You said that the ITA use
was lowest in the low-volume centers but also that the acuity was
the highest. Are you sure there was not a relationship between
lack of ITA use and patients being sicker when they went for sur-
gical intervention?
Dr Shahian. Well, the trend adjusted for acuity still showed the
same finding. Granted, the absolute differences are small. For all
these differences, many of them are statistically significant because
we have such a large sample size, but there was about a 1% or 2%
difference, and the lowest use among all programs—and some of
them had very low use rates—were at the low-volume end. We
had some programs with 70% or 60% ITA use, and they are all
at the low end of the volume spectrum. I do not think that is com-
pletely accounted for by acuity or other factors.ery c February 2010
